Company: TVRD
Filing Date: 2025-02-14
Form Type: S-4/A
Source: 0001104659-25-013053
Chunk: 916

Company: Tvardi Therapeutics, Inc.
Filing Date: 2025-02-14
Form: S-4/A
Chunk 916
---
 ​    | ​ |  4.67 | ​ | ​ |

As of December 31, 2023, the maturities of the Company’s operating lease liabilities were as follows (in thousands):

| Year Ended December 31,                             
 2024                                                | ​ 
 ​ | ​ 
 ​ | Amount 
 ​      |   | 123 | ​ | ​ 
 ​ |
|:----------------------------------------------------|:--|:--|:-------|:--|----:|:--|:--|
| 2025                                                | ​ | ​ | ​      | ​ |  94 | ​ | ​ |
| 2026                                                | ​ | ​ | ​      | ​ | 129 | ​ | ​ |
| 2027                                                | ​ | ​ | ​      | ​ |  88 | ​ | ​ |
| Total lease payments                                | ​ | ​ | ​      | ​ | 434 | ​ | ​ |
| Less: imputed interest                              | ​ | ​ | ​      | ​ | -66 | ​ | ​ |
| Present value of lease liabilities                  | ​ | ​ | ​      | ​ | 368 | ​ | ​ |
| Less: operating lease liabilities, current portion  | ​ | ​ | ​      | $ |  93 | ​ | ​ |
| Operating lease liabilities, net of current portion | ​ | ​ | ​      | $ | 275 | ​ | ​ |

8. Redeemable Convertible Preferred Stock The Company has issued Series A preferred stock and Series B preferred stock, which are collectively referred to as the Preferred Stock. As of December 31, 2023 and 2022, the Company authorized the issuance of 29,723,540 shares of Preferred Stock, par value of $0.001 per share, of which 9,499,999 have been designated Series A preferred stock and 20,223,541 have been designated Series B preferred stock. Series A Preferred Stock During 2018, the Company entered into the Series A preferred stock purchase agreements for 8,550,340 shares of Series A preferred stock with par value of $0.001 each at a price $1.00 per share, or the Series A

F-106

TABLE OF CONTENTS

8. Redeemable Convertible Preferred Stock (continued) Original Issue Price, with a group of investors for net proceeds of $8.4 million, or the Series A Financing. In addition, in connection with the